Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small c...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2013-05, Vol.5 (5), p.1599-1600
Main Authors: XUE, XINYING, XUE, QINGLIANG, LIU, YUXIA, PAN, LEI, WANG, KAIFEI, ZHANG, LINA, WANG, NA, YANG, BING, WANG, JIANXIN
Format: Article
Language:English
Subjects:
Cancer therapies
Case reports
Chemotherapy
combination treatment
gefitinib
Histology
Inhibitor drugs
interstitial lung disease
Lung cancer
Lung diseases
Mutation
non-small cell lung cancer
Oncology
Patients
prednisolone
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2013.1212